Profile data is unavailable for this security.
About the company
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
- Revenue in HKD (TTM)61.70m
- Net income in HKD-582.73m
- Incorporated2018
- Employees178.00
- LocationAntengene Corp LtdUgland HousePO Box 309SHANGHAI KY1-1104ChinaCHN
- Websitehttps://www.antengene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Health Group Inc | 27.17m | -62.38m | 99.54m | 41.00 | -- | 0.9813 | -- | 3.66 | -0.0627 | -0.0627 | 0.0273 | 0.1019 | 0.1547 | -- | 0.2559 | 647,010.40 | -35.50 | 6.84 | -47.26 | 9.52 | 42.55 | 74.98 | -229.55 | 19.19 | -- | -1,310.95 | -- | 0.00 | 63.67 | -18.51 | -267.82 | -- | 30.37 | -- |
| Sirnaomics Ltd | 0.00 | -637.43m | 280.44m | 90.00 | -- | 147.49 | -- | -- | -8.39 | -8.39 | 0.00 | 0.0217 | 0.00 | -- | -- | 0.00 | -110.32 | -- | -136.58 | -- | -- | -- | -- | -- | -- | -3.25 | -- | -- | -- | -- | 10.88 | -- | -- | -- |
| Clover Biopharmaceuticals Ltd | 31.80m | -973.15m | 282.76m | 323.00 | -- | -- | -- | 8.89 | -0.7803 | -0.7803 | 0.0255 | -0.7066 | 0.0119 | 0.014 | 98.80 | 82,175.72 | -36.27 | -- | -405.86 | -- | 54.86 | -- | -3,060.03 | -- | 0.4426 | -- | -- | -- | -- | -- | 94.35 | -- | -- | -- |
| Antengene Corp Ltd | 61.70m | -582.73m | 364.44m | 178.00 | -- | 0.3333 | -- | 5.91 | -0.9448 | -0.9448 | 0.10 | 1.62 | 0.035 | 0.6597 | 1.57 | 306,976.90 | -33.06 | -53.57 | -37.16 | -58.94 | 84.84 | -- | -944.43 | -1,987.01 | 5.66 | -23.74 | 0.1663 | -- | -57.97 | -- | 3.38 | -- | 202.03 | -- |
| Kintor Pharmaceutical Ltd | 0.00 | -1.01bn | 420.65m | 175.00 | -- | 0.9762 | -- | -- | -2.36 | -2.36 | 0.00 | 0.963 | 0.00 | 0.1411 | -- | 0.00 | -70.41 | -50.15 | -87.57 | -58.43 | -- | -27.62 | -- | -10,511.41 | 1.56 | -111.48 | 0.3788 | -- | -- | -- | -11.15 | -- | -32.49 | -- |
| HighTide Therapeutics Inc | 0.00 | -660.85m | 437.56m | 66.00 | -- | 0.6656 | -- | -- | -1.42 | -1.42 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -87.01 | -- | -118.34 | -- | -- | -- | -- | -- | -- | -- | 0.0404 | -- | -- | -- | -393.76 | -- | -- | -- |
| JW (Cayman) Therapeutics Co Ltd | 190.31m | -690.94m | 514.81m | 323.00 | -- | 0.3136 | -- | 2.71 | -1.68 | -1.68 | 0.4614 | 3.95 | 0.0747 | 1.87 | 11.48 | 478,163.50 | -27.11 | -39.77 | -31.71 | -44.00 | 50.40 | -- | -363.06 | -1,316.81 | 2.76 | -- | 0.2043 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
| Brii Biosciences Ltd | 0.00 | -292.12m | 679.38m | 95.00 | -- | 0.2157 | -- | -- | -0.4003 | -0.4003 | 0.00 | 4.31 | 0.00 | -- | -- | 0.00 | -8.89 | -- | -9.01 | -- | -- | -- | -- | -- | -- | -- | 0.007 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
| Genor Biopharma Holdings Ltd | 15.92m | -578.31m | 857.97m | 28.00 | -- | 0.7257 | -- | 53.88 | -1.14 | -1.14 | 0.0313 | 2.27 | 0.0093 | 0.0178 | 0.2277 | 153,116.50 | -33.87 | -55.46 | -39.06 | -63.73 | 97.59 | 66.56 | -3,638.27 | -14,819.18 | 5.73 | -- | 0.003 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
| Sunho Biologics Inc | -100.00bn | -118.07m | 924.33m | -- | -- | 1.53 | -- | -- | -0.8765 | -0.8765 | -- | 3.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.77 | -4,626.67 | 0.0516 | -- | -- | -- | -155.25 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Antengene Corp Ltd's reporting currency: Hong Kong Dollar HKD
3.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research (Hong Kong) Ltd.as of 31 Jul 2024 | 7.48m | 1.11% |
| Zeal Asset Management Ltd.as of 31 Dec 2023 | 6.32m | 0.94% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 5.02m | 0.74% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.82m | 0.27% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.51m | 0.22% |
| Dimensional Fund Advisors LPas of 31 May 2024 | 355.50k | 0.05% |
| Dimensional Fund Advisors Ltd.as of 30 Jun 2024 | 57.66k | 0.01% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 17.50k | 0.00% |
| DFA Australia Ltd.as of 31 Jul 2024 | 2.53k | 0.00% |
| American Century Investment Management, Inc.as of 31 Jul 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.
